MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE
Pavlo GonĨar | Lightrocket | Getty Images
Pfizer on Monday said he would stop development its experimental anti-obesity and diabetes pill, lotiglipronedue to elevated liver enzymes in once-daily patients in intermediate clinical studies.
The one elevated enzymes often indicate damage to cells in the liver, but the pharmaceutical giant says no patients have experienced liver-related symptoms or side effects.
New York-based Pfizer said it would instead focus on its own another oral anti-obesity drugdanuglipron, which is fully involved in the second phase of the clinical trial.
This study showed that body weight was reduced after patients with type 2 diabetes took high doses of danugliprone twice a day for 16 weeks. the results Pfizer released last month.
The company expects to complete plans for a phase 3 clinical trial program for danugliprone by the end of 2023. Pfizer added that it is also developing a version of danugliprone that patients take once a day instead of twice.
“We look forward to analyzing the Phase 2 results of danugliprone and selecting a dose and titration schedule that will maximize therapeutic benefit as well as safety and tolerability,” William Sessa, Pfizer’s chief scientific officer of internal medicine, said in a news release.
Lotigliprone, danugliprone and Novo NordiskThe successful weight loss injections Ozempic and Wegovy are part of a class of drugs called glucagon-like peptide-1 agonists.
They mimic a hormone produced in the gut called GLP-1, which signals the brain when a person is full.
Medicines can also help people manage type 2 diabetes by stimulating the release of insulin from the pancreas and lowering blood sugar levels.
Oral drugs such as Pfizer’s danugliprone could offer an advantage over frequent injections. Novo Nordisk and Eli Lilly they also develop their own experimental pills for obesity and diabetes.
A new class of obesity drugs is sparking public interest and causing a gold rush in the weight loss industry. But there is still uncertainty about their availability, and questions remain about how long patients should take the drugs to lose unwanted weight.
Some people who stop taking their medication complain of a weight rebound which is difficult to control.
More than 2 in 5 adults are obese, according to the National Institutes of Health. About 1 in 11 adults are severely obese.
.
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE
Source